Echelon Wealth Partners restated their buy rating on shares of Trulieve Cannabis (OTCMKTS:TCNNF) in a research note released on Wednesday morning, AnalystRatings.com reports. Echelon Wealth Partners currently has a $21.00 price target on the stock.
TCNNF has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a buy rating and issued a $20.00 price objective on shares of Trulieve Cannabis in a report on Monday, December 9th. Compass Point raised shares of Trulieve Cannabis from a neutral rating to a buy rating and increased their price objective for the stock from $11.00 to $17.00 in a report on Monday, December 2nd. Finally, Craig Hallum began coverage on shares of Trulieve Cannabis in a report on Monday, December 16th. They issued a buy rating and a $20.00 price objective on the stock.
TCNNF stock opened at $11.14 on Wednesday. Trulieve Cannabis has a fifty-two week low of $7.46 and a fifty-two week high of $16.23. The firm’s 50-day simple moving average is $11.17 and its 200 day simple moving average is $10.18.
Trulieve Cannabis Corp. operates as a medical marijuana company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as directly to patients via home delivery. It produces approximately 150 stock keeping units, including nasal sprays, capsules, concentrates, syringes, cannabis flower in tamper-proof containers for vaporizers, topical creams, tinctures, and vape cartridge.
Featured Story: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.